ABSTRACT
Background Within eight weeks of primary Clostridioides difficile infection (CDI), as many as 30% of patients develop recurrent disease with the associated risks of multiple relapses, morbidity, and economic burden. There are no validated biomarkers predictive of recurrence during primary infection. This study demonstrates the potential of a simple test for identifying hospitalized CDI patients at low risk for disease recurrence.
Methods Forty-six hospitalized CDI patients were enrolled at Emory University Hospitals. Serum and MENSA samples prepared during weeks 1, 2, and 4 following symptom-onset were measured for antibodies specific for ten C. difficile antigens.
Results Among the 46 C. difficile-infected patients, nine (19.5%) experienced recurrence within eight weeks of primary infection. Among the 37 non-recurrent patients, 23 had anti-C. difficile MENSA antibodies specific for any of the three toxin antigens: TcdB-CROP, TcdBvir-CROP, and/or CDTb. Positive MENSA responses occurred within the first week post-symptom onset, including six patients who never seroconverted. A similar trend was observed in serum responses, but they peaked later and identified fewer patients (19/37). In contrast, none of the patients who subsequently recurred after hospitalization produced antibodies specific for the three C. difficile toxin antigens. IgA antibodies for the toxin antigens demonstrated the greatest predictive power for protection from recurrence.
Discussion The development of IgG and/or IgA antibodies for three C. difficile toxins in serum and/or MENSA has prognostic potential. These immunoassays measure nascent immune responses that reduce the likelihood of recurrence. Early identification of patients at-risk for recurrence can reduce costs and morbidity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Centers for Disease Control and Prevention through Research Contract #200-2015-88233 titled Antibody Secreting Cells (ASC) in Human Clostridium difficile Infection, Colonization, and Recurrence.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Emory and Dekalb Institutional Review Boards and the Grady Research Oversight Committee approved all protocols and procedures. Written informed consent was obtained from each patient prior to inclusion in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared Senior Authors
Conflicts of Interest: Author Natalie S. Haddad is a current full-time employee of MicroB-plex, Inc. Geena Kim, Shant Ohanian and Sophia Nozick were full-time employees of MicroB-plex, Inc., who generated samples and data reported in this manuscript. F. Eun-Hyung Lee, M.D., is the founder of MicroB-plex, Inc, and an Associate Professor at Emory University. She did not draw salary in this project, but she was actively engaged in grant-writing, project administration and production of the manuscript. John L. Daiss, Ph.D., works more than half-time for MicroB-plex, Inc., and also served as a Research Associate Professor at the University of Rochester Medical Center until June 2021. L. Edward Cannon was the CEO of MicroB-plex, Inc., at the time of this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
Funding Sources: This work was supported by Phase I and Phase II Research Contracts #200-21-88233 titled “Antibody secreting Cells (ASC) in Human Clostridium difficile Infection, Colonization and Recurrence” from the Centers for Disease Control and Prevention.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
